Physician profile
Ed Settle
NPI 1871598581
$527.90
in general payments reported to CMS, 2019-2025
12 companies · $161 in 2025
The $161 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.08 · 2023: $54.29 · 2024: $299 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $513.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $76.43 | 2023-2025 | Wegovy |
| Amgen INC. | $73.99 | 2023-2024 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $73.82 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.13 | 2024-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $44.00 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $41.68 | 2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $33.42 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals Lp | $31.03 | 2022-2024 | Flumist Quadrivalent |
| Abbvie INC. | $27.09 | 2024 | |
| Phathom Pharmaceuticals, INC. | $24.27 | 2024 | Voquezna |
| Axsome Therapeutics, INC. | $18.89 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.15 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ed Settle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.